MetaCap

BlossomHill Therapeutics (BLSM) vs Rezolute (RZLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rezolute is the larger company by market cap ($465.6 million vs $461.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%RZLT-16.42%
+72%+22%-28%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%RZLT-16.42%
+65%+19%-28%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus RZLT key metrics
MetricBLSMRZLT
Share price$14.51$3.92
Market cap$461.20M$465.58M
1-day change+0.69%-6.67%
YTD return—+66.10%
1-year return—-60.12%
5-year return—-26.87%
EPS (TTM)$-10.38$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-77.60M
52-week high$27.99$11.17
52-week low$11.02$1.07
Distance from 52-week high-48.16%-64.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+143.97%+175.51%
Average volume193.15K1.66M
Shares outstanding31.78M118.77M
Employees6963
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

BLSM vs RZLT FAQ

Which is bigger, BlossomHill Therapeutics or Rezolute?

Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $461.20M for BlossomHill Therapeutics (BLSM).

Are BlossomHill Therapeutics and Rezolute in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons